Application of human umbilical cord high-activity mesenchymal stem cells

Through the complete culture medium of high-active MSC prepared by TeSR-E8 Basal Medium and CloneR, combined with the whole tissue adherent culture method of laminin LN521 coating solution, the heterogeneity and low cell activity in human umbilical cord stem cell isolation technology were solved. The problem of obtaining highly active MSCs for anti-aging treatments, especially in ovarian aging.

CN118931830AActive Publication Date: 2024-11-12AOCHEN BIOLOGICAL (YUNNAN) CO LTD

Patent Information

Application Number
CN202411201527.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-12
Estimated Expiration
2044-08-29

AI Technical Summary

Technical Problem

The existing human umbilical cord stem cell isolation technology has heterogeneity, resulting in different efficacy results. The isolation method is complicated and the cell activity is not high, making it difficult to obtain highly active MSCs suitable for clinical applications.

Method used

Highly active MSC complete culture medium prepared by TeSR-E8 Basal Medium and CloneR, combined with laminin LN521 coating solution, high-active MSCs were obtained through tissue-wide adherent culture, simplifying the isolation process, improving cell activity, and freezing Technology preserves cells.

Benefits of technology

The stable preparation of high-active MSCs has been achieved, cell activity and proliferation ability have been improved, pluripotency and differentiation potential have been ensured, and it is suitable for anti-aging treatments, especially in ovarian aging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931830A_ABST
    Figure CN118931830A_ABST
Patent Text Reader

Abstract

The invention discloses application of human umbilical cord high-activity mesenchymal stem cells. The method comprises the following steps: separating HA-MSC from human umbilical cord tissues by using TeSR-E8 containing 5% CloneR and an LN521-Coated culture bottle, and establishing a separation, amplification and cryopreservation technical system of the HA-MSC. Compared with the conventionally cultured MSC, the HA-MSC prepared by the invention has the advantages of higher proliferative activity, smaller volume, higher nucleoplasm ratio and high expression of symbolic antigens SOX2, Nanog and OCT4 related to embryonic stem cells, has the potential of differentiating to nerves, myocardium and hepatobiliary progenitor cells from three germ layers, and has good anti-aging activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of human umbilical cord stem cells, and in particular to an anti-aging application of highly active human umbilical cord MSCs. Background Art

[0002] Mesenchymal stem cells (MSC) are a group of adult pluripotent stem cells with the ability to self-renew and differentiate. MSC can be obtained from almost all human tissues, such as fat, dental pulp, menstrual blood, placenta, amniotic fluid, umbilical cord and synovial fluid. MSC has immunomodulatory function, secretes cytokines and immune receptors, and regulates the microenvironment in host tissues. It has been proven that they have great therapeutic potential in cardiovascular diseases, autoimmune diseases, vascular ischemia, tissue damage and various degenerative diseases. Therefore, MSC has broad application prospects in disease prevention and treatment.

[0003] Since the heterogeneity of MSC morphology and function weakens its therapeutic effect, it introduces differences in clinical evaluation of effectiveness and mechanism research, which may partly explain why the data of MSC-based clinical trials are largely inconsistent. To address the differences in efficacy caused by heterogeneity, it has been reported that more potent and primitive MSC subpopulations have been isolated from MSCs from different tissues. Although these subpopulations have high proliferation and differentiation potential, whether they can maintain multi-lineage differentiation ability, similar to the plasticity of embryonic stem cells, remains to be determined.

[0004] The reported methods for isolating high-potential MSC subpopulations include physical separation, which separates trypsin-resistant, multidirectionally differentiated, and pressure-resistant cells based on their response to trypsin; and separation based on immune phenotype, which separates cell subtypes with pluripotency surface marker molecules by flow cytometry, or introduces exogenous genes for cell re-editing. These separation methods are relatively cumbersome, with low cell activity and low yield, making it difficult to obtain cell therapy quantities for subsequent efficacy studies, and safety is difficult to guarantee. In addition, most culture systems contain animal serum, which is not suitable for clinical translation. Summary of the invention

[0005] The purpose of the present invention is to provide an application of human umbilical cord highly active MSCs, especially for anti-aging effect.

[0006] The above technical objectives of the present invention are achieved through the following technical solutions:

[0007] A method for anti-aging using highly active human umbilical cord MSCs.

[0008] Use of human umbilical cord highly active MSCs in the preparation of anti-aging preparations.

[0009] Further preferably, the method for preparing the above-mentioned human umbilical cord highly active MSCs comprises the following steps:

[0010] The following steps are involved:

[0011] S1. Reagent preparation;

[0012] S2, primary culture;

[0013] S3, subculture;

[0014] Preferably, it also includes S4, high-activity MSC cryopreservation.

[0015] Further preferably, S1 includes:

[0016] S11. Preparation of high-activity MSC complete medium: Add TeSR-E8 Supplement to TeSR-E8 Basal Medium, invert and mix well, then add CloneR, and use 6.6% NaHCO 3 Adjust the pH value to 7.2-7.4 and store at 4℃ for future use;

[0017] S12. Preparation of high-activity MSC culture flask: Slowly thaw the laminin LN521 stock solution at 2-8°C and add 1× DPBS (Ca 2+ / Mg 2+ ) Dilute the laminin LN521 stock solution to obtain the coating solution, add the coating solution to the culture bottle to evenly cover the entire bottom of the bottle, and incubate at 2-8°C for later use;

[0018] Further preferably, S2 includes:

[0019] S21, washing the collected human umbilical cord to remove residual blood;

[0020] S22, breaking down the umbilical cord into small tissue pieces and transferring them into a high-activity MSC culture bottle;

[0021] S23, add high-activity MSC complete medium to the high-activity MSC culture bottle, shake the bottle slowly, and place it at 37°C and 5% CO 2 Primary culture was carried out in an incubator;

[0022] S24, on the 3rd day, add high-activity MSC complete medium, and then change the medium every 3-4 days

[0023] S25. During passage, the detached tissue pieces are collected and secondary adherent culture can be performed according to the above method;

[0024] Further preferably, S3 includes:

[0025] S31. Take out the cells from the incubator, discard the old culture medium, and gently rinse once with saline;

[0026] S32, primary high-activity MSCs were added with Recombinant Trypsin-EDTA Solution and placed at 37°C and 5% CO 2 Incubator for 3-5mins;

[0027] S33, after the cells were completely detached, an equal amount of highly active MSC complete medium was added to terminate the digestion, the cells were collected and added with normal saline, and centrifuged at 1500 rpm for 4 mins;

[0028] S34, discard the supernatant after centrifugation, add high-activity MSC complete medium, gently pipette to mix the cells, and count the number of live cells with trypan blue staining;

[0029] S35, according to 5000 cells / cm 2 The cells were seeded into new high-activity MSC culture flasks at a seeding density of

[0030] S36, placed at 37°C, 5% CO 2 The cells were cultured in an incubator for expansion;

[0031] Further preferably, S4 includes:

[0032] Select highly active MSCs in the logarithmic growth phase and digest them with Recombinant Trypsin-EDTA Solution. After the cells shrink and become round, add highly active MSC complete culture medium to terminate the process. Centrifuge at 1500rpm for 4 minutes, discard the supernatant, gently blow to make the cells uniform, and then divide them into sterile cryopreservation tubes. Put the cryopreservation tubes containing cells into a programmed cooling box in a -80℃ refrigerator. After 4 hours, store them in a -196℃ liquid nitrogen tank for later use.

[0033] Further preferably, in step S11, the ratio of TeSR-E8 Basal Medium, TeSR-E8 Supplement and CloneR is 24:1:1.

[0034] More preferably, in step S12, the laminin LN521 stock solution is diluted to 5 μg / ml.

[0035] Further preferably, in step S21, the human umbilical cord is repeatedly rinsed with physiological saline containing 100u / ml dual antibody.

[0036] Further preferably, the above anti-aging preparation is a preparation for preventing, improving and / or treating ovarian aging; more preferably, the preparation is a medicament.

[0037] A method for preparing human umbilical cord highly active MSCs, comprising any of the preparation steps defined above.

[0038] A human umbilical cord high-activity MSC is prepared by the above preparation steps.

[0039] More preferably, the human umbilical cord highly active MSCs have the functions of wound repair, cell repair, promotion of tissue / cell regeneration and differentiation, immune regulation, anti-aging, and the like.

[0040] A use of the human umbilical cord highly active MSCs in the preparation of cosmetics, health products and medicines.

[0041] More preferably, the human umbilical cord highly active MSCs are in the form of cell culture or lyophilized powder.

[0042] More preferably, the dosage form of the above-mentioned health products and medicines is selected from injections, oral preparations, tablets, capsules or patches.

[0043] More preferably, the above cosmetics also include common auxiliary agents such as antioxidants, stabilizers, emulsifiers, solubilizers, pigments and fragrances.

[0044] A use of the human umbilical cord highly active MSCs in preparing a preparation for preventing, improving or treating aging.

[0045] Further preferably, the human umbilical cord highly active MSCs are used to prepare medicaments for preventing, improving or treating physiological and / or pathological aging / functional impairment of skin, liver, heart, ovary, uterus, testis, muscle, nerve, kidney, immunity, metabolism, or systemic aging / functional impairment.

[0046] Further preferably, the above human umbilical cord highly active MSCs are used to prepare a preparation for preventing, improving and / or treating ovarian aging.

[0047] More preferably, the above preparation is a pharmaceutical preparation.

[0048] More preferably, the human umbilical cord highly active MSCs are used to prepare drugs for preventing, improving and / or treating aging.

[0049] More preferably, the human umbilical cord highly active MSCs are used to prepare anti-aging drugs.

[0050] More preferably, the human umbilical cord highly active MSCs are used to prepare anti-aging drugs.

[0051] Further preferably, the above human umbilical cord highly active MSCs are used for preparing drugs for preventing, improving and / or treating ovarian aging.

[0052] More preferably, the human umbilical cord highly active MSCs are used to prepare anti-ovarian aging drugs.

[0053] More preferably, the human umbilical cord highly active MSCs are used to prepare drugs for reversing ovarian aging.

[0054] More preferably, the above-mentioned medicine further comprises one or more pharmaceutically acceptable excipients, diluents or carriers.

[0055] A preparation comprising any one of the above-mentioned highly active human umbilical cord MSCs.

[0056] A medicament comprising any one of the above-mentioned highly active human umbilical cord MSCs.

[0057] A pharmaceutical composition comprising any one of the above-mentioned highly active human umbilical cord MSCs.

[0058] A pharmaceutical composition, characterized in that it comprises highly active MSCs prepared by the preparation method in any one of claims 1 to 7.

[0059] A pharmaceutical composition, the active ingredients of which are prepared by any of the above-mentioned methods for preparing human umbilical cord highly active MSCs; preferably, further comprising one or more pharmaceutically acceptable excipients, diluents or carriers.

[0060] Compared with the prior art, the present invention has the following beneficial effects:

[0061] First, improve the culture medium and supporting culture conditions, including TeSR-E8 culture medium, ClonR, cell density and recombinant laminin coating, aiming to create an overall in vivo ecological microenvironment suitable for primitive cells. In this culture condition, TeSR-E8 culture medium does not contain animal origin and has a low protein content. Only one growth factor, ClonR, is added to the entire culture condition, and the use of recombinant laminin coating maintains the high pluripotency of the cells. Under this condition, the primary culture is carried out by whole tissue adhesion. Compared with other separation methods, this method is simple and easy, and the time from the tissue being removed from the body to entering the incubator is shorter, which maximizes and maintains very high cell activity.

[0062] Secondly, the primary culture method allows the original cells or highly pluripotent cells in the tissue to be sorted out from the primary generation, and can be stably passaged and preserved, providing a prerequisite for subsequent expansion.

[0063] Third, compared with conventionally cultured MSCs, highly active MSCs have higher proliferation activity, smaller size, higher nuclear-cytoplasmic ratio, and high expression of embryonic stem cell-related marker antigens SOX2, Nanog, and OCT4. They have the potential to differentiate into neural, myocardial, and hepatic and intestinal progenitor cells derived from the three germ layers, indicating that this cell is a sub-totipotent stem cell among highly active MSCs.

[0064] Fourth, high-activity MSCs have a higher efficacy in treating macaque ovarian aging than conventionally prepared MSCs, and can improve the tissue structure and secretory function of the ovaries, regenerate follicles, and restore ovulation and menstruation, but fail to reproduce reproductive function. It was found that high-activity MSCs can reverse ovarian aging through multiple mechanisms such as differentiation into GC, reversing GC aging, resisting oxidative stress, inhibiting ovarian cell apoptosis, increasing vascular density, promoting ovarian GC division and proliferation, and specific marker molecule expression. The results provide a new technical method and scientific basis for the clinical treatment of ovarian aging. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 The figures are the morphology of umbilical cord HA-MSC and MSC under an inverted phase contrast microscope (×50); 1A: On the 8th day, HA-MSC cells can be seen growing scattered around the tissue mass in a short spindle shape (red circle); 1B: On the 12th day, HA-MSC formed large colonies, which were arranged like a school of fish; 1C: On the 10th day, MSC cells grew scattered around the tissue mass in a long spindle shape, resembling fibroblasts; 1D: On the 15th day, MSC colonies were arranged in a whorl shape.

[0066] Figure 2 The figures are the cell morphology of HA-MSC and MSC at three passages after passage under an inverted phase contrast microscope (×50); 2A, 2B, and 2C are P3, P6, and P9 of HA-MSC after passage, respectively, and each passage maintains a uniform short cell morphology; 2D, 2E, and 2F are P3, P6, and P9 of MSC after passage, respectively. With the increase of passages, the cell body becomes larger, the edges are irregular, some cells are polygonal, and the number of granules in the cytoplasm increases.

[0067] Figure 3 The P3 generation HA-MSC and MSC were dynamically observed under a holographic living cell microscope for 48 hours.

[0068] Figure 4 These are the growth curves of HA-MSC and MSC; 4A: The growth curves of P3 generation HA-MSC and MSC are typical "S" shapes; 4B: The growth curve of P9 generation HA-MSC remains unchanged, while the growth curve of P9 generation MSC tends to be flat, and the cell proliferation ability decreases.

[0069] Figure 5 is the population doubling time of HA-MSCs and MSCs.

[0070] Figure 6 This is the transmission electron microscopy of HA-MSC; 6A: Bar = 5um; 6B: Bar = 2um.

[0071] Figure 7 It is a MSC transmission electron microscope; 7A: Bar = 5 μm; 7B: Bar = 2 μm.

[0072] Figure 8 The nuclear-cytoplasmic ratio of HA-MSC and MSC is measured; 8A, 8B, and 8C are HA-MSC; 8D, 8E, and 8F are MSC, and 8G is the statistical result. Bar = 5 μm. n = 3, **P < 0.01.

[0073] Fig. 9 9A and 9B are the cell cycles of HA-MSC and MSC, respectively.

[0074] Fig.10 10A and 10B are the expression flow cytometry graphs of HA-MSC and MSC surface markers (CD73, CD105, CD90, CD34, CD45); 10A and 10B are the results of HA-MSC and MSC, respectively.

[0075] Fig.11 11A is the flow cytometric graph of the expression of surface markers (SSEA-3, SSEA-4, TRA-1-60) of HA-MSC and MSC; 11A and 11B are the results of HA-MSC and MSC, respectively.

[0076] Fig.12 Figure 12A and 12B are the WB electrophoresis images and their expression statistics, respectively.

[0077] Fig.13 It is to identify the tri-lineage differentiation ability of HA-MSC and MSC.

[0078] Fig.14 It is the identification of HA-MSC and MSC ectoderm differentiation marker molecule expression; DAPI locates the cell nucleus, and the secondary antibody is labeled with Cy3 to show red fluorescence. Bar = 20 μm. n = 3, ***P < 0.001, **P < 0.01. 14A and 14B are the fluorescence imaging and the statistical results of differentiation marker molecule expression, respectively.

[0079] Fig.15 It is the identification of the expression of mesodermal differentiation marker molecules of HA-MSC and MSC; DAPI locates the cell nucleus, and the secondary antibody is labeled with Cy3 to show red fluorescence. Bar=20μm. n=3, ***P<0.001, **P<0.01. 15A and 15B are the fluorescence imaging and statistical results of differentiation marker molecule expression, respectively.

[0080] Fig.16 It is the identification of HA-MSC and MSC endoderm differentiation marker molecule expression; DAPI locates the cell nucleus, and the secondary antibody is labeled with Cy3 to show red fluorescence. Bar=20μm. n=3, ***P<0.001. 16A and 16B are the fluorescence imaging and differentiation marker molecule expression statistical results, respectively.

[0081] Fig.17 This is a graph showing changes in serum AMH.

[0082] Fig.18 This is the abdominal ultrasound of the HA-MSC treatment group 5 months after transplantation.

[0083] Fig.19 is Masson staining of ovarian tissue (20×). 19A and 19B are tissue staining images and statistical results, respectively.

[0084] Fig. 20 This is the colonization of dual-mode labeled cells in ovarian tissue (40×).

[0085] Fig.21 is the detection of ROS level in ovarian tissue (40×). 21A and 21B are the fluorescence imaging and statistical results, respectively.

[0086] Fig. 22 22A and 22B are fluorescence imaging and statistical results, respectively.

[0087] Fig.23 is the ovarian cell proliferation and apoptosis assay (40×); Fig.23 A and 23B are the fluorescence imaging and statistical results of HA-MSC, respectively. Fig.23 C and 23D are the fluorescence imaging and statistical results of MSCs, respectively.

[0088] Fig.24 is the expression of ovarian granulosa-specific markers (40×); Fig.24 A and 24B are the fluorescence imaging and statistical results of HA-MSC, respectively. Fig.24 C and 24D are the fluorescence imaging and statistical results of MSCs, respectively.

[0089] Fig.25 Telomere length of macaques of different ages and changes after HA-MSC treatment.

[0090] Fig.26 This is the β-galactosidase staining of human ovarian granulosa cells (50×). Fig.26 A and 26B are the cell staining images and statistical results, respectively.

[0091] Fig. 27 It is the 3D holographic live cell dynamic observation of aged hGC and HA-MSC (600×); Fig. 27 A, Fig. 27 B shows the results before and after the addition of HA-MSC.

[0092] Fig.28 The morphological changes of MSCs and HA-MSCs induced into GCs in vitro (50×). Fig.28 A is the morphological change diagram of the in vitro induction process. Fig.28 B is the morphology of hGC cells.

[0093] Fig.29 It is a specific marker molecule for the induction of stem cells into GC in vitro (40×); Fig.29 A, 29B are the fluorescence imaging and statistical results of HA-MSC, Fig.29 C and 29D are the fluorescence imaging and statistical results of MSCs.

[0094] Fig.30 These are the changes in AMH secretion induced by HA-MSCs into GCs in vitro. DETAILED DESCRIPTION

[0095] The present invention will be described in detail below in conjunction with examples, but the examples provided herein are only for illustrative purposes and are not intended to limit the present invention.

[0096] the term

[0097] “HA-MSC” and “highly active MSC” and “highly active mesenchymal stem cells” are used interchangeably throughout the text.

[0098] "Anti-aging" means reversing, preventing, alleviating or inhibiting the progression of aging and aging-related diseases, disorders or conditions, or one or more symptoms of a disease, disorder or condition.

[0099] "Treat" means to slow down, alleviate, ameliorate or lessen at least one symptom of a disease, or to reverse its onset after onset.

[0100] "Prevention" refers to the process of taking action before a disease occurs to prevent the disease from developing or to reduce the severity or slow its development.

[0101] "Agent" refers to a substance that produces or is capable of producing an effect and may include, but is not limited to, chemicals, pharmaceuticals, drugs, biologics, small molecules, antibodies, nucleic acids, peptides, and proteins.

[0102] "Pharmaceutical composition" refers to a composition at any stage of the manufacturing process, including the final pharmaceutically acceptable product and any process intermediates thereof.

[0103] "Excipients" are additives other than the main drug in pharmaceutical preparations, and can also be called auxiliary materials. For example, preservatives, antioxidants, flavoring agents, aromatics, cosolvents, emulsifiers, solubilizers, osmotic pressure regulators, colorants, etc.

[0104] The various terms and phrases used in the present invention have general meanings known to those skilled in the art. Even so, the present invention still hopes to provide a more detailed description and explanation of these terms and phrases herein. If the mentioned terms and phrases are inconsistent with the known meanings, the meanings expressed in the present invention shall prevail.

[0105] Example 1: Preparation method of human umbilical cord highly active MSC (HA-MSC)

[0106] 1 Materials

[0107] 1.1 Source of human umbilical cord

[0108] The umbilical cords in this experiment were obtained from the Department of Obstetrics and Gynecology of the 920th Hospital of the Joint Logistics Support Force of the People's Liberation Army. The selected pregnant women were required to have no infectious diseases, no tumor diseases, no family history of genetic diseases, and no congenital diseases in the full-term fetus. With the consent of the pregnant women and their families, the "Informed Consent Form for Umbilical Cord Collection" was signed, and the umbilical cord was collected during delivery. The umbilical cord collection was approved by the Ethics Committee of the 920th Hospital of the Joint Logistics Support Force of the People's Liberation Army, with the approval number: 2019-036 (Section) -01.

[0109] 1.2 Main instruments

[0110]

[0111] 1.3 Main Reagents

[0112]

[0113]

[0114] 2. Experimental Methods

[0115] The following steps are involved:

[0116] S1. Reagent preparation

[0117] S1-1. Screening and preparation of culture medium:

[0118] S1-1-1. Based on DMEM / F12, gradually enrich the components of the culture medium, such as replacing bovine serum with human platelet lysate, replacing bovine serum albumin with human serum albumin, and gradually replacing components from animal origin with components from human origin, thereby reducing the immune rejection reaction caused by differences in species origin; there is also a practice of completely abandoning ingredients of animal origin based on DMEM / F12, that is, completely free of ingredients of animal origin (including those of human origin), adding trace elements such as selenium, vitamins, transferrin, insulin, basic fibroblast growth factor, as well as buffer pairs to maintain the pH stability of the solution, antioxidants and other substances. We tried to use DMEM / F12 as the basis, adding human platelet lysate to replace FBS, and observed that the cell proliferation ability remained good, but the in vitro osteogenic and adipogenic abilities were reduced. Then we continued to add transferrin, insulin, basic fibroblast growth factor, etc., and observed that the cell morphology was closer to the original stem cells, the cells were small and translucent, with clear outlines, a high nuclear-cytoplasmic ratio, and the in vitro tri-lineage differentiation ability remained good. The above additives played a key role in maintaining the stemness of stem cells; in order to prevent and control the cloning efficiency of single stem cells, we also added CloneR, and observed that the cells still maintained a good proliferation ability at a low density of seeding. Finally, the HA-MSC complete medium described in S1-1-2 was determined.

[0119] S1-1-2. Preparation of HA-MSC complete medium: Add 20 ml TeSR-E8 Supplement to 480 ml TeSR-E8 Basal Medium, invert and mix, then add 20 ml CloneR, and use 6.6% NaHCO 3 Adjust the pH value to 7.2-7.4 and store in a refrigerator at 4°C for future use.

[0120] S1-2. Optimization of the culture environment

[0121] S1-2-1, Optimization and screening of coating solution: Starting from how to create a primitive microenvironment for stem cell growth, we considered optimizing the 2D space. We changed from using serum and / or mouse embryonic fibroblast trophoblast to using gelatin, Matrigel, and LN521 to pre-treat the culture flask. After repeated experiments, we found that primary cells rarely grew after gelatin coating. We first excluded the gelatin coating treatment and studied Matrigel and LN521 extracellular matrices. We found that both can maintain a relatively primitive cell state for our isolated cells. Finally, we determined the coating solution and culture flask treatment method as in S1-2-2.

[0122] S1-2-2. Coating solution for HA-MSC culture flask: slowly thaw the laminin LN 521 stock solution at 2-8°C and add 1× DPBS (Ca2+ / Mg 2+ ) Dilute the laminin LN521 stock solution to 5 μg / ml to prepare the STSC coating solution. 2 Add 5 ml of coating solution to evenly cover the entire bottom of the bottle, incubate at 2-8°C overnight, and record the bottle as LN521-CoatedT75cm 2 .

[0123] S2. Primary culture of human umbilical cord HA-MSCs

[0124] S2-1. In a clean bench, repeatedly rinse the collected human umbilical cord with physiological saline containing 100u / ml of dual antibody, remove the residual blood and place it in a 10cm culture dish.

[0125] S2-2, first use tissue scissors to cut the umbilical cord into 1mm pieces 3 Each small tissue block was transferred to a 1.5 ml EP tube. The tissue in the EP tube was separated with iris scissors until it became a paste and then transferred to LN521-Coated T75cm 2 In culture flask.

[0126] S2-3. After adding 3 ml of HA-MSC complete culture medium to each bottle, shake the bottle slowly to evenly disperse the microtissue blocks. Indicate the culture time, cell name and generation number on the bottle and place it at 37°C and 5% CO. 2 Primary culture was carried out in an incubator.

[0127] S2-4, on the 3rd day, add 3 ml of complete culture medium, and then change the medium every 3-4 days, and observe the cell growth under an inverted phase contrast microscope. When changing the medium, gently suck up the old culture medium with a pipette and discard it. Move gently and try not to move the tissue blocks attached to the wall.

[0128] S2-5. During subculturing, the detached tissue pieces are collected and secondary adherent culture can be performed according to the above method.

[0129] Subculture of S3 and HA-MSCs

[0130] When the primary cells grow to about 80% fusion, they need to be subcultured. The specific steps are as follows:

[0131] S3-1. Take out the cells from the incubator, discard the old culture medium in the clean bench, and gently rinse once with saline.

[0132] S3-2. Add 4 ml of Recombinant Trypsin-EDTA Solution to each bottle of primary HA-MSC and place at 37°C and 5% CO 2 incubator for 3-5mins.

[0133] S3-3. After the cells are completely detached under a microscope, add an equal amount of HA-MSC complete medium to terminate digestion. Collect the cells into a 50 ml centrifuge tube, add physiological saline, and centrifuge at 1500 rpm for 4 minutes.

[0134] S3-4. After centrifugation, discard the supernatant, add 2 ml of complete culture medium, gently pipette to mix the cells, and count the number of living cells by trypan blue staining.

[0135] S3-5, according to 5000 cells / cm 2 The cells were seeded into new LN521-Coated T75 culture flasks at a seeding density of

[0136] S3-6. Indicate the culture time, cell name and generation number on the bottle and place at 37°C and 5% CO. 2 The cells were cultured in an incubator and photographed at each generation.

[0137] S4. Highly active MSC cryopreservation

[0138] HA-MSCs in the logarithmic growth phase were selected and digested with Recombinant Trypsin-EDTA Solution. After the cells shrank and became round, the corresponding complete medium was added to terminate the process. After centrifugation at 1500 rpm for 4 minutes, the supernatant was discarded. TM D10Cryopreservation Medium, use a pipette to gently blow the cells evenly, then divide them into sterile cryopreservation tubes, add 1.8ml of liquid to each cryopreservation tube. Write the cell name, batch number and cryopreservation time on the cryopreservation tube, and keep a record. Put the cryopreservation tube containing cells into a programmed cooling box in a -80℃ refrigerator, and place it in a -196℃ liquid nitrogen tank for 4 hours for storage.

[0139] Example 2: Preparation method of conventional MSCs

[0140] The conventional MSC preparation method includes the following steps:

[0141] S1. Reagent preparation

[0142] S1-1. Preparation of MSC complete culture medium: Add 55 ml of fetal bovine serum to 500 ml of DMEM / F12 culture medium and use 6.6% NaHCO 3 Adjust the pH value to 7.2-7.4 and store in a refrigerator at 4°C for future use.

[0143] S1-2, MSC uses ordinary T75cm 2 Culture flask.

[0144] S2. Primary culture of human umbilical cord MSCs

[0145] S2-1. In a clean bench, repeatedly rinse the collected human umbilical cord with physiological saline containing 100u / ml of dual antibody, remove the residual blood and place it in a 10cm culture dish.

[0146] S2-2, first use tissue scissors to cut the umbilical cord into 1mm pieces 3 Each small tissue block was transferred to a 1.5ml EP tube. The tissue in the EP tube was separated with iris scissors until it became a paste and then transferred to a regular T75cm 2 In culture flask.

[0147] S2-3. After adding 3 ml of MSC complete culture medium to each bottle, shake the bottle slowly to evenly disperse the microtissue blocks. Indicate the culture time, cell name and generation number on the bottle and place it at 37°C and 5% CO. 2 Primary culture was carried out in an incubator.

[0148] S2-4, on the 3rd day, add 3 ml of complete culture medium, and then change the medium every 3-4 days, and observe the cell growth under an inverted phase contrast microscope. When changing the medium, gently suck up the old culture medium with a pipette and discard it. Move gently and try not to move the tissue blocks attached to the wall.

[0149] S2-5. During subculturing, the detached tissue pieces are collected and secondary adherent culture can be performed according to the above method.

[0150] S3. Subculture of MSCs

[0151] When the primary cells grow to about 80% fusion, they need to be subcultured. The specific steps are as follows:

[0152] S3-1. Take out the cells from the incubator, discard the old culture medium in the clean bench, and gently rinse once with saline.

[0153] S3-2: Add 4 ml of 0.25% trypsin-EDTA solution to each bottle of primary MSC and place at 37°C and 5% CO 2 incubator for 3-5mins.

[0154] S3-3. After the cells are completely detached under a microscope, add an equal amount of MSC complete medium to terminate digestion. Collect the cells into a 50 ml centrifuge tube, add physiological saline, and centrifuge at 1500 rpm for 4 minutes.

[0155] S3-4. After centrifugation, discard the supernatant, add 2 ml of complete culture medium, gently pipette to mix the cells, and count the number of living cells by trypan blue staining.

[0156] S3-5, according to 5000 cells / cm 2 The cells were seeded into new T75 culture flasks at a seeding density of

[0157] S3-6. Indicate the culture time, cell name and generation number on the bottle and place at 37°C and 5% CO. 2 The cells were cultured in an incubator and photographed at each generation.

[0158] S4. Conventional MSC cryopreservation

[0159] Select MSCs in the logarithmic growth phase and digest them with Recombinant Trypsin-EDTA Solution. After the cells shrink and become round, add the corresponding complete medium to terminate the process. Centrifuge at 1500 rpm for 4 minutes and discard the supernatant. Add the prepared freezing solution (containing 10% DMSO and 5% glycerol) to MSCs and adjust the cell density to 4×10 6 / ml, use a pipette to gently blow to make the cells uniform, then divide them into sterile cryopreservation tubes, and add 1.8ml of liquid to each cryopreservation tube. Write the cell name, batch number and cryopreservation time on the cryopreservation tube, and keep a record. Put the cryopreservation tube containing cells into a programmed cooling box and place it in a -80℃ refrigerator. After 4 hours, place it in a -196℃ liquid nitrogen tank for storage.

[0160] Example 3: Comparison of highly active MSCs and conventionally cultured MSCs

[0161] In the following text and in the drawings of the specification, HA-MSC refers to highly active MSC, and MSC refers to conventionally cultured MSC.

[0162] 1. Growth morphology of primary culture of human umbilical cord HA-MSC and MSC

[0163] The two stem cells were cultured using the whole tissue adherence method without stripping off the blood vessels and capsule. In the culture system of TeSR-E8 Medium containing 5% ClonR, umbilical cord HA-MSCs were observed to grow scattered around the tissue block on the 8th day in a culture bottle coated with laminin LN 521. The umbilical cord HA-MSCs were small in shape, short and spindle-shaped, with a high nuclear-cytoplasmic ratio. A large number of cells were observed to swim out from the periphery of the tissue block on the 12th day after the medium was changed ( Figure 1 A, 1B). On the 10th day, umbilical cord MSC cells were observed to grow sporadically around the tissue mass in an elongated spindle shape, and on the 15th day, they grew in a whirlpool-like fusion ( Figure 1 C, 1D). HA-MSCs are smaller in size, have a higher nuclear-cytoplasmic ratio, and have fewer foreign cells in primary cells compared to MSCs.

[0164] 2. Subculture of human umbilical cord HA-MSC and MSC and dynamic observation of 3D holographic living cells

[0165] 2.1 Subculture

[0166] When the primary cells grow to about 80% confluence, they are subcultured. The two stem cells subcultured to P3 maintain their morphology and grow well ( Figure 2 A, 2D). Compared with cells from the same umbilical cord, HA-MSCs maintained a short rod-shaped morphology and good activity until P9. Figure 2 B, 2C); The P9 cells of MSC increased in size, gradually became wider and flatter in shape, some cells were polygonal, and the number of granules in the cytoplasm increased, showing an aging state ( Figure 2 E, 2F).

[0167] 2.23D holographic dynamic observation of living cells

[0168] Under a 3D holographic live cell microscope, HA-MSC and MSC of the P3 generation were dynamically observed for 48 hours, and one cell field of view was selected for dynamic observation. HA-MSC is small in size, with regular cell body edges, little cytoplasm, obvious nucleus and obvious nucleolus, and dense genetic material with strong refractive index in the nucleus, indicating that it is in the early stage of division. Before the end of the 48-hour observation, HA-MSC is preparing to enter the division stage, and MSC is larger in size, with irregular cell bodies, and a small number of particles can be seen in the cytoplasm. The cell nucleus is small and the nucleolus is obvious. Before the end of the 48-hour observation, the MSC has not divided ( Figure 3 ). Figure 3 The HA-MSC cell nucleus is large, the cytoplasm is small, and the nuclear staining material gradually increases, indicating that it is about to enter the division stage. The MSC cell volume is irregular, with more cytoplasm, a large nucleus, a prominent nucleolus, and the cell body is constantly changing and wandering (×400).

[0169] 3. Growth curve and population doubling time of human umbilical cord HA-MSCs and MSCs

[0170] 3.1 Growth curve

[0171] The growth curves of HA-MSC and MSC were measured by MTS method. The two types of cells of P3 were in the retention period 2 days after inoculation, and the proliferation was not obvious. They entered the logarithmic growth period 3-7 days later, and the cells grew vigorously and had good activity ( Figure 4 A); on the 8th day, it entered the plateau phase, and the growth curve showed a typical "S" shape. Compared with the same generation HA-MSC, the logarithmic growth curve of P9 MSC was flat, and it entered the plateau phase earlier, indicating that the cell proliferation ability was reduced ( Figure 4 B).

[0172] 3.2 Population doubling time

[0173] The population doubling time is the time required for the number of cells to double under culture conditions, reflecting the proliferation ability of cells. The population doubling time (PDT) of the two cells was calculated by taking the OD value of the logarithmic growth phase on the growth curve. The PDT of P3-HA-MSC was lower than that of P3-MSC (P < 0.01); the PDT of P9-HA-MSC was significantly lower than that of P9-MSC (P < 0.001); indicating that the proliferation ability of HA-MSC of P3 and P9 was higher than that of MSC ( Figure 5 ).

[0174] 4. Transmission electron microscopy observation and nuclear-cytoplasmic ratio of human umbilical cord HA-MSC and MSC

[0175] 4.1 Transmission electron microscopy observation

[0176] HA-MSC cells under transmission electron microscopy are slightly edematous. The cell membrane is intact, with abundant pseudopodia and protrusions on the surface. The cell is slender in shape, with uniform intracellular matrix and evenly distributed organelles. The cell nucleus (N) is irregular in shape, with an intact nuclear membrane and slightly marginal heterochromatin ( Figure 6 A); Mitochondria (M) are abundant, most of them have clear structures, intact membranes, parallel cristae, and the matrix in some membranes becomes lighter and the cristae decrease; the rough endoplasmic reticulum (RER) is obviously expanded, and a large number of floccules can be seen in the endoplasmic reticulum pool, endoplasmic reticulum retention, Golgi apparatus (Go) hypertrophy, and capsule expansion. There are a small number of autophagolysosomes (ASS), and 2 can be seen in this field of view ( Figure 6 B).

[0177] Under the transmission electron microscope, the MSC cells were slightly edematous as a whole, some organelles were slightly swollen, and the cytoplasm was evenly distributed. The cell membrane was intact, with abundant pseudopodia (PS) around it, and a small number of organelles in the membrane were vacuolated. The nucleus (N) was large and irregular in shape, the nuclear membrane was intact, the perinuclear space was normal, the chromatin was uniform, the nucleolus (Nu) was large, and the structure was dense ( Figure 7 A); Mitochondria (M) are abundant, most of them are slightly swollen, the matrix inside the membrane becomes pale, the cristae are broken and reduced, and in some severe cases, the cristae disappear and become vacuolar; the rough endoplasmic reticulum (RER) is partially expanded, and a small amount of floccules can be seen in the endoplasmic reticulum pool. Lysosomes (Ly) exist occasionally. Glycogen granules (GL) are locally aggregated. There are a large number of autophagic lysosomes (ASS), and 5 ( Figure 7 B).

[0178] 4.2 Nuclear-cytoplasmic ratio

[0179] The nuclear-cytoplasmic ratio was calculated by measuring 3 cells in each group. The nuclear-cytoplasmic ratio of HA-MSC was significantly higher than that of MSC (P < 0.01). Figure 8 .

[0180] 5. Cell Cycle

[0181] By detecting the cell cycle by flow cytometry, 79.48% of HA-MSCs and 63% of MSCs in the P3 generation were in the G0 / G1 phase, which was consistent with the characteristics of MSCs cultured in vitro. HA-MSCs have a high proportion of G0 / G1 phases, proving that they have a high differentiation potential ( Fig. 9 ).

[0182] 6. Expression of surface markers

[0183] Both HA-MSC and MSC highly expressed MSC-related surface markers CD73, CD105, and CD90, and low or no expression of CD34 and CD45 (Table 1, Fig.10 ), which is consistent with the phenotypic characteristics of MSC; HA-MSC partially expressed ESC-related surface markers SSEA-3, SSEA-4 and TRA-1-60, and MSC was affected by the serum in the culture environment, with SSEA-4 expression of 25.8%, and no expression of SSEA-3 and TRA-1-60 (Table 1, Fig.11 ).

[0184] Table 1 Expression percentage of surface markers of HA-MSC and MSC

[0185]

[0186] 7. Western blot (WB) to detect the expression of pluripotency transcription factors

[0187] WB was used to detect the expression of two stem cell pluripotency transcription factors. It was found that HA-MSC expressed pluripotency transcription factors SOX2, OCT4, and Nanog. Analysis of the gray value of the target band showed that the expression levels of SOX2 and Nanog were significantly higher than those of MSC (P < 0.001); while MSC only expressed OCT4, which had no difference in expression level with HA-MSC (P > 0.05) ( Fig.12 ), indicating that HA-MSCs are in an earlier stage of development than MSCs.

[0188] 8. Identification of trilineage differentiation ability

[0189] Adipogenic differentiation: After 14 days of adipogenic differentiation, red lipid droplets can be seen in the cytoplasm after Oil Red O staining; osteogenic differentiation: After 21 days of induction, calcium nodules can be stained red by Alizarin Red; chondrogenic differentiation: After 14 days of induction, cartilage collagen matrix can be seen stained blue by Argine Blue. From the staining degree analysis, HA-MSC has stronger ability to differentiate into three lineages than MSC ( Fig.13 ).

[0190] 9. Expression levels of marker molecules after differentiation of the three germ layers

[0191] After the two stem cells were induced to differentiate into three germ layers, two specific markers were selected for each germ layer (ectoderm markers: Nestin, PAX6; mesoderm markers: Meso-CXCR4, Brachyury (T); endoderm markers: Endo-CXCR4, SOX-17) and the expression of markers was detected by immunofluorescence. The results showed that HA-MSC could differentiate into the ectoderm, with the cell morphology showing a slender neural progenitor cell-like shape, and immunofluorescence identification showed the expression of ectoderm-specific markers; at the same time, it could also differentiate into the mesoderm and endoderm and express the specific markers of the corresponding germ layers, while MSC could only differentiate into the mesoderm ( Figure 14-16 ).

[0192] Example 4: Ovarian aging reversal test

[0193] 1. Animal Source

[0194] The macaques in this experiment were purchased from the Experimental Animal Center of the Kunming Institute of Zoology, Chinese Academy of Sciences, with the experimental animal production license number: SCXK (Yunnan) K2017-0003. The young male macaques were 8 years old and weighed 2 kg; the female macaques were 22-28 years old and weighed 3.5-6.5 kg. They were kept in the Experimental Animal Center of the Basic Medical Laboratory of the 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, with the experimental animal use license number: SYXK (Military) 2017-0051. They were of normal size and raised in an ordinary environment. The environment was clean and hygienic during the breeding period, and the temperature was suitable. All animal studies were approved by the Experimental Animal Ethics Committee of the 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, with the approval number: 2020-034 (Section) -01.

[0195] 2. Screening of macaques with ovarian aging

[0196] Nine elderly female macaques that met the inclusion criteria were screened out, with obvious aging phenotypes, dull or partially lost fur, sparse teeth, and poor mobility. Abdominal ultrasound showed: ovarian atrophy or no ovarian follicles, less than 2 follicles or no follicles. Peripheral blood sex hormones were monitored for two consecutive months, among which E2, P, and AMH of elderly macaques were significantly lower than those of macaques in the reproductive period, inhibin B was below the detection limit, and FSH and LH had no cross-reaction with human reagents and were not detected.

[0197] 3. Animal Grouping and HA-MSC Transplantation Treatment

[0198] The 9 selected elderly female macaques were randomly divided into HA-MSC treatment group (n=3), MSC treatment group (n=3), and elderly model group (n=3). 7Double-labeled HA-MSCs and MSCs were transplanted via the hind limb vein at a dose of 1 cell / kg / time. The elderly model group was infused with an equal volume of normal saline as a control for three consecutive days. No adverse reactions occurred after the infusion.

[0199] 4. Evaluation of the efficacy of HA-MSC transplantation therapy

[0200] 4.1 Mating and menstrual observation

[0201] After cell transplantation, the monkeys were housed together with young male macaques. Two macaques in the HA-MSC group resumed menstruation on the 7th and 10th day after cell transplantation, one of which resumed menstruation on the 29th day, and the rest showed no signs of menstruation. On the 90th day after transplantation, the macaques in the HA-MSC group that resumed menstruation twice were found to have mated with young male macaques.

[0202] 4.2 Serum AMH monitoring

[0203] Compared with the level before transplantation, the AMH levels of the HA-MSC treatment group and the MSC treatment group increased at 1 month after transplantation. The increase in the HA-MSC treatment group continued until the second month and then began to decline. At 5 months, it was slightly higher than the level before transplantation. The MSC treatment group increased at 1 month and then declined to the level before transplantation. The AMH level of the elderly model group did not increase during the observation period ( Fig.17 ).

[0204] 4.3 Abdominal ultrasound of macaques

[0205] HA-MSC treatment group: 1 / 3 (94346) left ovary: 0.95cm×0.57cm×0.57cm, OV=0.16cm 3 , 2 follicles in the left ovary: 1, 0.23cm×0.22cm, 2, 0.49cm×0.45cm; right ovary: 0.9cm×0.5cm×0.49cm, follicle: 0.18cm×0.17cm, see ( Fig.18 ).

[0206] MSC treatment group: 2 / 3 (99324, 98318) 99324 Left ovary: 1.16cm×0.55cm×0.48cm, OV=0.16cm 3 , follicle: 0.64cm×0.53cm, right ovary not shown. 98318 Left ovary: 0.98cm×0.63cm×0.53cm, OV=0.17cm 3 , follicle: 0.66cm×0.25cm, right ovary: 0.79cm×0.31cm×0.27cm, OV=0.04cm 3 , no follicles. Elderly model group: bilateral ovaries were not shown.

[0207] 4.4 Ovarian gross anatomy and histological changes

[0208] At 5 months, the macaques were euthanized and the specimens were collected. The gray-white bilateral ovaries of the HA-MSC treatment group were clearly visible, and the volume was larger than that of the old control group and the MSC treatment group. HE staining results showed that follicles of all levels were visible in the HA-MSC treatment group, and the medullary stroma was neatly arranged with clear boundaries; no mature follicles were seen in the MSC treatment group, and a small number of primary follicles and primordial follicles were seen; atretic follicles were occasionally seen in the old control group, and a large amount of fibrous connective tissue was seen.

[0209] 4.5 Changes in fibrous deposition in ovarian tissue

[0210] Masson staining was used to reflect the fibrosis of ovarian tissue. Collagen fibers in the tissue were blue, and muscle fibers, cellulose and red blood cells were red. The staining results showed that there were a large number of collagen fibers deposited in the medulla and interstitium of the elderly control group, with a large fiber area and obvious fibrosis; there was a small amount of collagen fiber deposition under the cortex in the HA-MSC treatment group, with a smaller area, and the degree of fibrosis was significantly reduced compared with the elderly control group (P < 0.001); there was some collagen fiber deposition in the medulla of the MSC treatment group, and the degree of fibrosis was significantly reduced compared with the elderly control group (P < 0.001) ( Fig.19 ).

[0211] 5. Mechanism of HA-MSCs in reversing ovarian aging

[0212] 5.1 Colonization of dual-labeled HA-MSCs

[0213] Under the fluorescence microscope, the HA-MSC treatment group showed green fluorescence expression of eGFP-labeled cells (red circle), and blue was the cell nucleus. No green fluorescence was found in the MSC treatment group and the elderly model group. In addition, Prussian blue staining solution showed that the HA-MSC treatment group had SPION-labeled cells colonized in the subcortex, medulla, and around the follicles of the ovary. SPION was blue (red circle) and the cell nucleus was red ( Fig. 20 ).

[0214] 5.2 Changes in reactive oxygen species content in ovarian tissue

[0215] The DHE method was used to detect the level of reactive oxygen species (ROS) in ovarian tissue. DHE will be oxidized into red fluorescence in the presence of ROS in the tissue, and the intensity of red fluorescence is proportional to the level of ROS in the tissue. The results showed that the ROS level in the elderly model group was higher, and the ROS level decreased after cell therapy. The ROS level in the HA-MSC treatment group was lower than that in the MSC treatment group (P < 0.05), indicating that HA-MSC inhibited the production of reactive oxygen species in ovarian tissue, suggesting an anti-oxidative stress effect ( Fig.21 ).

[0216] 5.3 Changes in vascular density in ovarian tissue

[0217] Immunofluorescence technology was used to detect the vascular endothelial cell marker CD34 to reflect the density of blood vessels in ovarian tissue. Red fluorescence indicates CD34-positive cells and blue indicates cell nuclei. The results showed that CD34 expression was the lowest in the elderly model group. CD34 expression increased after cell therapy, indicating an increase in vascular density and angiogenesis. The CD34 expression in the HA-MSC treatment group was higher than that in the MSC treatment group (P < 0.05), indicating that HA-MSC has a stronger ability to promote angiogenesis than MSC ( Fig. 22 ).

[0218] 5.4 Changes in ovarian cell proliferation and apoptosis

[0219] Immunofluorescence technique was used to detect ovarian cell proliferation and apoptosis using Ki67 antibody and Tunel staining, respectively. In proliferation detection, red fluorescence indicates Ki67-positive proliferating cells, and blue indicates cell nuclei; in apoptosis detection, red fluorescence indicates positive apoptotic cells, and blue indicates cell nuclei. The results showed that compared with the elderly model group, the proliferation rate of ovarian cells increased and the apoptosis rate decreased after cell transplantation, among which HA-MSC had a greater ability to promote proliferation and inhibit apoptosis than MSC (P < 0.01) ( Fig.23 ).

[0220] 5.5 Expression of ovarian granulosa cell-specific markers

[0221] Immunofluorescence technology was used to detect the expression of AMH and FSHR, the specific marker molecules of granulosa cells. Red fluorescence indicated AMH and FSHR positive cells, and blue indicated cell nuclei. The results showed that compared with the elderly model group, the expression of AMH and FSHR increased after cell therapy, and the expression level in the HA-MSC treatment group was greater than that in the MSC treatment group (P < 0.01) ( Fig.24 ).

[0222] 5.6 Measurement of relative telomere length in peripheral blood mononuclear cells

[0223] The Q-PCR method was used to detect the relative length of peripheral blood mononuclear telomeres in 6 age groups and 1 month (T1) and 3 months (T3) after HA-MSC treatment. The results of the relative telomere length measurement in the 6 age groups showed that the telomere length gradually shortened with age. After 1 month of HA-MSC treatment, the telomere length of the 22-year-old group was extended to between 13 and 17 years old. After 3 months of treatment, the telomere length was measured again and returned to the pre-treatment ( Fig.25 ).

[0224] 5.7 Co-culture of human ovarian granulosa cells and HA-MSCs in vitro

[0225] 5.7.1 Transwell co-culture of human ovarian granulosa cells and HA-MSCs

[0226] Put H 2 O 2 The aged hGC was co-cultured with HA-MSC and MSC respectively, and the ability to reverse the aged hGC was identified by β-galactosidase staining. The aged cells will be stained blue by β-galactosidase. The results showed that both HA-MSC and MSC could reverse the aged hGC after 72 hours of co-culture. Compared with the aged model group, the number of blue-stained senescent cells decreased (P < 0.001), and there was no difference with the normal control group. There was no difference in the ability of the two cells to reverse the aged hGC ( Fig.26 ).

[0227] 5.7.2 Dynamic changes of 3D holographic living cells co-cultured with human ovarian granulosa cells and HA-MSCs

[0228] hGC was treated with 273 mM H 2 O 2 After 24 hours of treatment, the results of 36 hours of observation under a 3D holographic live cell microscope showed that the number of granular autophagosomes in the 4 hGC cells photographed under the field of view increased, the cell activity was poor, there was no proliferation within 36 hours, and the cells were in a state of senescence ( Fig. 27 A). After the addition of HA-MSCs, two HA-MSCs entered the original observation field, one of which began to divide into two STSCs after attaching to the wall, and the other HA-MSC also began to divide 6 hours later. After the addition of HA-MSCs, the autophagic lysosomes in the original four aged hGCs gradually decreased, and the hGCs began to divide one by one. By the end of the 36-hour observation period, all four hGCs had divided and proliferated ( Fig. 27 B).

[0229] 5.8 Detection of the ability of HA-MSC to induce granulocytes in vitro

[0230] After 20 days of induction of HA-MSC and MSC by the prepared granulocyte complete induction solution, the morphology of some cells gradually changed from fibroblast-like to round and oval-like, similar to granulocytes ( Fig.28 ) The induced cells were identified by immunofluorescence technique. Both cells expressed granulosa cell-specific markers AMH and FSHR. The ability of HA-MSC to induce granulosa cells was stronger than that of MSC ( Fig.29 In order to identify whether the cells were induced into functional granulosa cells, the collected culture supernatant was tested for AMH. The results showed that a small amount of AMH secretion began at D4 of induction, and the amount of AMH secretion gradually increased as the induction time prolonged ( Fig.30 ).

[0231] In summary, compared with conventionally cultured MSCs, HA-MSCs have higher proliferation activity, smaller size, higher nuclear-cytoplasmic ratio, and highly expressed embryonic stem cell-related marker antigens SOX2, Nanog, and OCT4. They have the potential to differentiate into neural, myocardial, and hepatic and intestinal progenitor cells derived from the three germ layers, indicating that this cell is a sub-totipotent stem cell among UC-MSCs.

[0232] Moreover, it was confirmed that HA-MSC has a higher efficacy than conventionally prepared MSC in treating macaque ovarian aging, and can improve the tissue structure and secretory function of the ovaries, regenerate follicles, and restore ovulation and menstruation, but it failed to reproduce reproductive function. It was found that HA-MSC can reverse ovarian aging through multiple mechanisms such as differentiation into GC, reversing GC aging, anti-oxidative stress, inhibiting ovarian cell apoptosis, increasing vascular density, promoting ovarian GC division and proliferation, and specific marker molecule expression. The results provide a new technical method and scientific basis for the clinical treatment of ovarian aging.

[0233] This specific embodiment is merely an explanation of the present invention and is not a limitation of the present invention. After reading this specification, those skilled in the art may make non-creative modifications to the present embodiment as needed. However, as long as they are within the scope of the claims of the present invention, they are protected by the patent law.

Claims

1. A use of highly active human umbilical cord mesenchymal stem cells (MSC) in the preparation of an anti-aging preparation, characterized in that: The method for preparing the highly active MSC comprises the following steps: S1. Reagent preparation S11. Preparation of high-activity MSC complete medium: Add TeSR-E8Supplement to TeSR-E8 BasalMedium, mix thoroughly by inversion, then add CloneR, adjust pH to 7.2-7.4 with 6.6% NaHCO3, and store at 4°C for later use; S12. Preparation of high-activity MSC culture flask: slowly thaw the laminin LN521 stock solution at 2-8°C and add 1× DPBS (Ca 2+ / Mg 2+ ) Dilute the laminin LN521 stock solution to obtain the coating solution, add the coating solution to the culture bottle to evenly cover the entire bottom of the bottle, and incubate at 2-8°C for later use; S2. Primary Culture S21, washing the collected human umbilical cord to remove residual blood; S22, breaking down the umbilical cord into small tissue pieces and transferring them into a high-activity MSC culture bottle; S23, add high-activity MSC complete medium to the high-activity MSC culture bottle, shake the bottle slowly, and place it in an incubator at 37°C and 5% CO2 for primary culture; S24, on day 3, add high-activity MSC complete medium, and then change the medium every 3-4 days; S25. During subculturing, the detached tissue pieces are collected and secondary adherent culture can be performed according to the above method; S3. Subculture S31. Take out the cells from the incubator, discard the old culture medium, and gently rinse once with saline; S32, primary high-activity MSCs were added with Recombinant Trypsin-EDTA Solution and placed in an incubator at 37°C and 5% CO2 for 3-5 minutes; S33, after the cells were completely detached, an equal amount of highly active MSC complete medium was added to terminate the digestion, the cells were collected and added with normal saline, and centrifuged at 1500 rpm for 4 mins; S34, discard the supernatant after centrifugation, add high-activity MSC complete medium, gently pipette to mix the cells, and count the number of live cells with trypan blue staining; S35, according to 5000 cells / cm 2 The cells were seeded into new high-activity MSC culture flasks at a seeding density of S36. Place in an incubator at 37°C and 5% CO2 for expansion culture.

2. The use according to claim 1, characterized in that The method for preparing highly active MSCs further comprises S4, cryopreservation of highly active MSCs, Select highly active MSCs in the logarithmic growth phase and digest them with Recombinant Trypsin-EDTA Solution. After the cells shrink and become round, add highly active MSC complete culture medium to terminate the process. Centrifuge at 1500rpm for 4 minutes, discard the supernatant, gently blow to make the cells uniform, and then divide them into sterile cryopreservation tubes. Put the cryopreservation tubes containing cells into a programmed cooling box in a -80℃ refrigerator. After 4 hours, store them in a -196℃ liquid nitrogen tank for later use.

3. The use according to any one of claims 1 to 2, characterized in that: In step S11, the ratio of TeSR-E8BasalMedium, TeSR-E8 Supplement, and CloneR is 24:1:

1.

4. The use according to claim 3, characterized in that In step S12, the laminin LN521 stock solution is diluted to 5 μg / ml.

5. The use according to claim 4, characterized in that In step S21, the human umbilical cord is repeatedly rinsed with physiological saline containing 100u / ml dual antibody.

6. The use according to claim 5, characterized in that The anti-aging preparation is a preparation for preventing, improving and / or treating aging.

7. The use according to claim 6, characterized in that The anti-aging preparation is a medicine for preventing, improving and / or treating ovarian aging, which also includes one or more pharmaceutically acceptable excipients, diluents or carriers.

8. A pharmaceutical composition, characterized in that The invention is prepared by the use according to any one of claims 1 to 7.

Citation Information

Patent Citations

  • Method for culturing human embryo stem cell by using umbilical cord source mesenchymal stem cell

    CN102250835A

  • Human umbilical cord mesenchymal stem cell preparation method

    CN110551684A

  • Preparation method and application of umbilical cord and placenta mesenchymal stem cells

    CN111321115A

Cited By

  • Pharmaceutical composition containing high-activity umbilical cord MSC

    CN119405783A